QuickView: First Xadago sales; US decision by end Q116
Xadago for the treatment of Parkinson’s disease is now generating initial sales in Europe following first launch in Germany, leading to royalty income to Newron from partner Zambon. The US regulatory review was recently extended by three months to end March 2016. Beyond Xadago, Newron has prioritised development of orphan drug sarizotan for Rett syndrome (a rare genetic condition) with a pivotal trial planned to start in Q415. Partnering candidate NW-3509 for schizophrenia is also advancing.Newron Pharmaceuticals is a clinical stage biopharmaceutical company. Co. is focused on the development of drugs for the treatment of central nervous system disorders and pain. Co.'s pipeline include, Xadago® (safinamide), for the treatment of Parkinson's disease (PD) and PD Levodopa-induced dyskinesia; Sarizotan, for the treatment of Rett syndrome (Orphan drug status); Evenamide (NW-3509), for the treatment of Schizophrenia and Clozapine-treatment-resistant schizophrenia; and Ralfinamide for patients with specific rare pain indications (neuropathic pain).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.